Eli Lilly's Strategic Pivot: Building a Neuroscience Division Through Major Acquisition

Eli Lilly diversifies from GLP-1 drugs with a $7.8B neuroscience acquisition. The move aims to counter expected price pressures and build a new growth pillar alongside its weight-loss franchises.

In a strategic move to diversify its revenue streams, pharmaceutical giant Eli Lilly has announced a definitive agreement to acquire Centessa Pharmaceuticals for approximately $7.8 billion. This acquisition marks a significant foray into the neuroscience sector, signaling the company's intent to reduce its long-term reliance on its blockbuster GLP-1 diabetes and weight-loss medications.

Financial Performance and Competitive Pressures

Eli Lilly recently reported robust financial results for its 2025 fiscal year, with revenue reaching $65.18 billion—a substantial 44.7% increase over the prior year. Looking ahead, management has provided 2026 revenue guidance in the range of $80 to $83 billion, with projected earnings per share expected to fall between $33.50 and $35.00.

Despite this strong performance, driven largely by its Mounjaro and Zepbound franchises which command roughly 60% of the weight-loss market, the competitive landscape is shifting. The company anticipates intensified competition, particularly in the oral GLP-1 segment, leading to an expected price decline in the low to mid-teens percentage range for 2026. This projected drop is notably steeper than the 6% global headwind experienced in 2025. Furthermore, policy changes such as Medicare's expansion of coverage and capping of out-of-pocket costs for certain treatments at $50 per month are adding incremental margin pressure.

The Centessa Rationale and Pipeline Catalysts

The timing of the Centessa acquisition is a direct response to these market dynamics. Centessa brings specialized research pipelines focused on sleep disorders and neuroactive compounds, areas where Eli Lilly has had limited presence. The integration is designed to establish a second major growth pillar alongside its established metabolism business.

Eli Lilly's near-term pipeline holds additional catalysts. A key FDA decision for orforglipron—the company's first oral GLP-1 drug, already marketed as Foundayo—is anticipated in the second quarter of 2026. The company is also advancing a $2.75 billion artificial intelligence partnership with Insilico Medicine. On the operational side, production capacity for incretin doses was successfully increased to 1.6 times the prior year's level in the first half of 2025, largely resolving previous supply constraints.

Market Sentiment and Price Targets

Wall Street analysts maintain a bullish outlook on the stock. The current average price target stands at $1,209, representing a significant premium to recent trading levels. The share price has recently pulled back from its 52-week high of $1,132.

This acquisition underscores a strategic broadening of Eli Lilly's therapeutic portfolio, positioning neuroscience as a complementary engine for future growth as it navigates an evolving market for its flagship products.